MY202673A - Modifying binding molecules to minimize pre-existing interactions - Google Patents
Modifying binding molecules to minimize pre-existing interactionsInfo
- Publication number
- MY202673A MY202673A MYPI2020006898A MYPI2020006898A MY202673A MY 202673 A MY202673 A MY 202673A MY PI2020006898 A MYPI2020006898 A MY PI2020006898A MY PI2020006898 A MYPI2020006898 A MY PI2020006898A MY 202673 A MY202673 A MY 202673A
- Authority
- MY
- Malaysia
- Prior art keywords
- binding molecules
- minimize
- minimize pre
- interactions
- modifying binding
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862695988P | 2018-07-10 | 2018-07-10 | |
| PCT/US2019/041203 WO2020014358A1 (en) | 2018-07-10 | 2019-07-10 | Modifying binding molecules to minimize pre-existing interactions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY202673A true MY202673A (en) | 2024-05-14 |
Family
ID=67544330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2020006898A MY202673A (en) | 2018-07-10 | 2019-07-10 | Modifying binding molecules to minimize pre-existing interactions |
Country Status (16)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021000239A (es) | 2018-07-10 | 2021-03-25 | Regeneron Pharma | Modificacion de moleculas de union para minimizar interacciones preexistentes. |
| WO2025260062A2 (en) * | 2024-06-13 | 2025-12-18 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting interleukin-4 receptor subunit alpha (il-4ra) |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US6329508B1 (en) | 1989-09-07 | 2001-12-11 | Alkermes, Inc. | Transferrin receptor reactive chimeric antibodies |
| US6056957A (en) * | 1994-08-04 | 2000-05-02 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-5 |
| US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| AU2004245038A1 (en) | 2003-06-02 | 2004-12-16 | Alexion Pharmaceuticals, Inc. | De-immunized anti-CD3 antibody |
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| EP2006380A4 (en) | 2006-03-23 | 2010-08-11 | Kyowa Hakko Kirin Co Ltd | AGONIST ANTIBODY AGAINST THE HUMAN THROMBOPOIETINE RECEPTOR |
| US7608693B2 (en) * | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| WO2009091240A1 (en) | 2008-01-15 | 2009-07-23 | Stichting Sanquin Bloedvoorziening | Method and kits for detecting antibodies against therapeutic antibodies |
| NZ592611A (en) * | 2008-10-10 | 2013-01-25 | Emergent Product Dev Seattle | A single chain fusion protein that binds to tcr complex and does not induce or induces a minimally detectable cytokine release |
| CA2741114A1 (en) | 2008-10-24 | 2010-04-29 | Cornelis Lammert Verweij | Biomarkers for predicting the development of chronic autoimmune diseases |
| DE102008061522A1 (de) | 2008-12-10 | 2010-06-17 | Biontech Ag | Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung |
| WO2010122148A1 (en) * | 2009-04-24 | 2010-10-28 | Boehringer Ingelheim International Gmbh | An improved antibody domain and antibody fragments and antibodies based thereon |
| TWI507525B (zh) * | 2009-06-26 | 2015-11-11 | Regeneron Pharma | 具天然免疫球蛋白形式之易分離的雙專一性抗體 |
| WO2011074965A1 (en) | 2009-12-17 | 2011-06-23 | Stichting Sanquin Bloedvoorziening | Methods and means for counteracting an activity of an fc domain |
| JP2014518632A (ja) | 2011-06-01 | 2014-08-07 | モアハウス スクール オブ メディスン | ケモカイン−免疫グロブリン融合ポリペプチド、組成物、その作製および使用の方法 |
| MY167125A (en) | 2011-08-17 | 2018-08-13 | Glaxo Group Ltd | Modified proteins and peptides |
| SG11201506451UA (en) | 2013-03-06 | 2015-09-29 | Merrimack Pharmaceuticals Inc | Anti-c-met tandem fc bispecific antibodies |
| TWI755763B (zh) * | 2013-06-04 | 2022-02-21 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
| SMT202300039T1 (it) | 2013-09-13 | 2023-03-17 | Beigene Switzerland Gmbh | Anticorpi anti-pd1 e loro uso come terapia e per diagnostica |
| IL315136A (en) * | 2014-02-21 | 2024-10-01 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4rantagonist |
| WO2015187596A2 (en) | 2014-06-02 | 2015-12-10 | Regeneron Pharmaceuticals, Inc. | Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses |
| CN106999587B (zh) | 2014-10-02 | 2023-09-29 | 希望之城公司 | 多价中间表位，中间表位结合抗体及其用途 |
| CN107076761B (zh) * | 2014-11-05 | 2020-05-05 | 豪夫迈·罗氏有限公司 | 用于测定针对效应子功能抑制的人或人源化药物抗体的抗药物抗体的方法 |
| CA3246946A1 (en) * | 2014-11-14 | 2025-11-29 | Sanofi Biotechnology | Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist |
| US9139653B1 (en) | 2015-04-30 | 2015-09-22 | Kymab Limited | Anti-human OX40L antibodies and methods of treatment |
| EP4015533A1 (en) * | 2015-10-29 | 2022-06-22 | F. Hoffmann-La Roche AG | Anti-variant fc-region antibodies and methods of use |
| WO2017075259A1 (en) | 2015-10-30 | 2017-05-04 | Genentech, Inc. | Anti-factor d antibody formulations |
| EP3515944A4 (en) * | 2016-09-19 | 2020-05-06 | Celgene Corporation | METHOD FOR TREATING IMMUNE DISEASES USING PD-1 BINDING PROTEINS |
| TW201829463A (zh) * | 2016-11-18 | 2018-08-16 | 瑞士商赫孚孟拉羅股份公司 | 抗hla-g抗體及其用途 |
| PT3515465T (pt) * | 2017-08-18 | 2024-03-04 | Regeneron Pharma | Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r |
| EP3713966A1 (en) | 2017-11-22 | 2020-09-30 | Vacara AB | Antibodies to citrullinated proteins |
| MX2021000239A (es) | 2018-07-10 | 2021-03-25 | Regeneron Pharma | Modificacion de moleculas de union para minimizar interacciones preexistentes. |
| US20220244252A1 (en) | 2019-06-07 | 2022-08-04 | Sanquin Innovatie B.V. | Methods and compounds for typing rheumatoid factors |
-
2019
- 2019-07-10 MX MX2021000239A patent/MX2021000239A/es unknown
- 2019-07-10 EA EA202190228A patent/EA202190228A1/ru unknown
- 2019-07-10 AU AU2019302642A patent/AU2019302642B2/en active Active
- 2019-07-10 EP EP19749878.5A patent/EP3820891A1/en active Pending
- 2019-07-10 KR KR1020217002619A patent/KR102938177B1/ko active Active
- 2019-07-10 CN CN201980042886.7A patent/CN112543768B/zh active Active
- 2019-07-10 MY MYPI2020006898A patent/MY202673A/en unknown
- 2019-07-10 SG SG11202012835RA patent/SG11202012835RA/en unknown
- 2019-07-10 TW TW108124293A patent/TWI838388B/zh active
- 2019-07-10 BR BR112020026784-8A patent/BR112020026784A2/pt unknown
- 2019-07-10 IL IL316308A patent/IL316308B1/en unknown
- 2019-07-10 AR ARP190101943A patent/AR115730A1/es unknown
- 2019-07-10 JP JP2020572773A patent/JP7665339B2/ja active Active
- 2019-07-10 TW TW113110335A patent/TW202428612A/zh unknown
- 2019-07-10 CA CA3104873A patent/CA3104873A1/en active Pending
- 2019-07-10 WO PCT/US2019/041203 patent/WO2020014358A1/en not_active Ceased
- 2019-07-10 US US16/507,880 patent/US11448651B2/en active Active
-
2020
- 2020-12-27 IL IL279803A patent/IL279803A/en unknown
-
2021
- 2021-01-07 MX MX2025013509A patent/MX2025013509A/es unknown
-
2022
- 2022-09-19 US US17/933,185 patent/US12523659B2/en active Active
-
2025
- 2025-04-09 JP JP2025064335A patent/JP2025100662A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL316308A (en) | 2024-12-01 |
| EP3820891A1 (en) | 2021-05-19 |
| US12523659B2 (en) | 2026-01-13 |
| KR102938177B1 (ko) | 2026-03-11 |
| KR20210030378A (ko) | 2021-03-17 |
| AR115730A1 (es) | 2021-02-17 |
| US20230266333A1 (en) | 2023-08-24 |
| JP7665339B2 (ja) | 2025-04-21 |
| US20200018754A1 (en) | 2020-01-16 |
| US11448651B2 (en) | 2022-09-20 |
| TWI838388B (zh) | 2024-04-11 |
| WO2020014358A1 (en) | 2020-01-16 |
| MX2021000239A (es) | 2021-03-25 |
| AU2019302642B2 (en) | 2025-10-30 |
| SG11202012835RA (en) | 2021-01-28 |
| CN112543768B (zh) | 2024-05-03 |
| CA3104873A1 (en) | 2020-01-16 |
| AU2019302642A1 (en) | 2021-02-25 |
| BR112020026784A2 (pt) | 2021-03-30 |
| IL316308B1 (en) | 2026-07-01 |
| JP2021531245A (ja) | 2021-11-18 |
| EA202190228A1 (ru) | 2021-04-14 |
| CN112543768A (zh) | 2021-03-23 |
| IL279803A (en) | 2021-03-01 |
| TW202428612A (zh) | 2024-07-16 |
| TW202021984A (zh) | 2020-06-16 |
| MX2025013509A (es) | 2025-12-01 |
| JP2025100662A (ja) | 2025-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20210326A (es) | Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor | |
| SA519402463B1 (ar) | بولي ببتيدات رابطة لمستقبل ترانسفيرين معالجة بالهندسة الوراثية | |
| MX2020000957A (es) | Anticuerpos anti-sirp-alfa y metodos relacionados. | |
| CL2017000954A1 (es) | Moléculas de unión a antígeno biespecificas activadoras de células t | |
| EP4219559A3 (en) | Antibodies for lilrb2 | |
| PH12019502087A1 (en) | Anti-par2 antibodies and uses thereof | |
| PH12018500216A1 (en) | Antibody constructs for cd70 and cd3 | |
| MX2018001159A (es) | Constructos de anticuerpo para flt3 y cd3. | |
| MX2016017271A (es) | Moleculas con especificidad para cd45 y cd79. | |
| JO3788B1 (ar) | تراكيب جسم مضاد لـ egfrviii وcd3 | |
| AR106201A1 (es) | Moléculas biespecíficas de unión a antígeno activadoras de células t | |
| MX2021008367A (es) | Constructos de anticuerpos para cdh19 y cd3. | |
| EA201490454A1 (ru) | Тернесит в качестве активатора для латентно-гидравлических и пуццолановых веществ | |
| UA108199C2 (uk) | АНТИТІЛО ПРОТИ α5β1 І ЙОГО ЗАСТОСУВАННЯ | |
| MX2019011759A (es) | Composicion para producir tagatosa y procedimiento de produccion de tagatosa usando el mismo. | |
| MX342034B (es) | Proteinas monovalentes que se unen a antigenos. | |
| MX391238B (es) | Metodo y dispositivo para la verificacion de privilegios | |
| BR112018073945A2 (pt) | métodos para tratamento de miastenia grave generalizada refratária | |
| PH12019500551A1 (en) | Antibody specifically binding to il-17a and functional fragment thereof | |
| MY180940A (en) | Novel antibodies directed to fc gamma receptor iib and fc epsilon receptor | |
| MX2025013509A (es) | Modificacion de moleculas de union para minimizar interacciones preexistentes | |
| MX2016014416A (es) | Anticuerpos anti-her3 que se unen a la horquilla beta de her3. | |
| MX2022006316A (es) | Composicion para la preparacion de alulosa y procedimiento para la preparacion de alulosa mediante el uso de la misma. | |
| MX2021004430A (es) | Proceso para producir (met-) acrilato de amonio. | |
| UA122791C2 (uk) | Антитіло до igf-1r та його застосування для діагностики раку |